Kite, a Gilead Company, announced findings from two new analyses of the landmark ZUMA-7 trial of Yescarta® (axicabtagene ciloleucel), the largest and longest follow-up of a CAR T-cell therapy versus standard of care in patients with relapsed or refractory large B-cell lymphoma...
Body of evidence grows from ZUMA-7 study supporting initial treatment with Yescarta® CAR T-cell therapy for patients with r/r LBCL
